Patients with COPD, characterized by an FEV1/FVC ratio of less than 70%, often experience shortness of breath, chest tightness, chronic cough, frequent respiratory infections, lack of energy, and wheezing. Those at MMRC grade 2 need to stop and catch their breath even during normal walking. Studies show that COPD patients take 8-12 minutes longer to get out of bed compared to healthy individuals. More frustratingly, COPD is currently incurable, posing a constant threat of hypoxia, with patients battling low oxygen levels with every breath.
In China, there are approximately 90 million COPD patients. The prevalence among adults is 8.9%, rising to 13.7% for those over 40 years old. The rate is higher in rural areas compared to urban areas, and men are 2.2 times more likely to be affected than women.
The research team at Chenpon is joining this battle! We have designed the new "Keshun" inhalation drug delivery device and a new therapeutic drug formulation. We are looking forward to better clinical outcomes and are working with top scientists in the field to win the fight against the threat to our patients' breathing!
Patient-centered drug development means devising research plans that maximize patient benefits and fully respect patient preferences.
Through our innovations and medications, we strive to improve the lives of others. This is the mission of every researcher at Chenpon.
